The British Equine Veterinary Association (BEVA) welfare award 2008, sponsored by The Blue Cross, has been presented to the Retraining of Racehorses (RoR) organisation for their contributions to equine welfare in support of the re-training and re-homing of racehorses.
The award, which was introduced by BEVA in conjunction with The Blue Cross animal welfare charity eight years ago, is a formal recognition of significant contributions made by veterinary surgeons and others to equine welfare.
It was presented to Ron Huggins, trustee of the ROR and an owner and breeder of racehorses, at the 47th BEVA Annual Congress in Liverpool on Friday 12 September 2008, by Kerstin Alford, equine welfare director of The Blue Cross.
Kerstin said: "The financial support that RoR provides for charitable racehorse rehabilitation centres, together with their education programme to help owners and riders of former racehorses, make them very worthy recipients of this award."
Di Arbuthnot, director of operations said: "RoR are delighted to receive this prestigious award to recognise the work the charity does for former racehorses to provide them with a life after racing."
Retraining of Racehorses was established in 2000 by the British Horseracing Authority. Its aim is to raise funds from the British racing industry to provide and maintain facilities for the care, retraining and rehoming of former racehorses. Under the direction of the chairman of the trustees Peter Deal, the RoR has become recognised as a vital component of the racing industry.
The Blue Cross was founded in 1897 to care for working horses on the streets of London, and equine welfare still plays a vital role in its work today. The charity rehabilitates and rehomes over a hundred horses and ponies every year at its equine centres in Burford (Oxon) and Rolleston-on-Dove (Staffordshire). A third facility in Northiam (East Sussex) provides rest and retirement for Blue Cross equines.
The RCVS has brought out a new publication to help members of the veterinary and veterinary nursing professions understand their legal and professional obligations regarding controlled drugs.
Controlled Drugs Guidance is a consolidation of existing advice and guidance on controlled drugs from a number of organisations including the RCVS itself, the Veterinary Medicines Directorate (VMD), the British Small Animal Veterinary Association (BSAVA) and the Home Office. The guide also gives details of the existing legislation concerning controlled drugs, namely the Misuse of Drugs Act and associated regulations.
The guidance provides advice on a variety of topics to reflect the common queries the RCVS Advice Team receives, such as storage, destruction and disposal; keys and keyholders for controlled drugs cabinets; controlled drugs in vehicles; and veterinary nurses administering controlled drugs.
The publication also deals with specific controlled drugs such as ketamine which, on 30 November 2015, was rescheduled to a Schedule 2 controlled drug, meaning that it is now subject to the same strict storage, prescription, dispending, destruction and record-keeping requirements as other medicines in this Schedule.
Laura McClintock, Standards and Advisory Manager at the RCVS, said: “We hope that this publication will help members of the profession navigate the often complex legislative and professional requirements regarding controlled drugs, as well as imparting best practice advice on how they should be stored and disposed and so on.
"This publication has also been endorsed by our colleagues in the Home Office, VMD and BSAVA and, because this is an area that is subject to regular change, we will make sure to keep it up-to-date as and when the regulations change."
The publication is available to download from the RCVS website at www.rcvs.org.uk/publications
Pfizer, manufacturer of the wormer Strongid™-P has launched a new promotional campaign. Love your horse is based on simple, straightforward and unbiased educational messages to help ensure the optimum health and wellbeing of horses and ponies in the UK.
Pfizer's veterinary adviser Ben Gaskell said: “Simplistically, the three key tools for the horse owner to understand are diagnostics, worming and pasture management. If these tools are used in combination with specialist advice, then the horse owner will be able to provide a sustainable, reliable and cost-effective worm control strategy for their horse.”
At the core of the campaign is a new range of four highly informative and uncomplicated leaflets directed at every type of horse owner: Do you need to worm; Choosing and using the right wormer; Managing your pasture and Worming and Your new horse.
“Each leaflet has been designed to work as a stand-alone piece or can be presented as a smart, matching series of four,” said Helen Shirley, brand manager for Strongid™-P. “The leaflets can be displayed in-store in a distinctive counter-top leaflet dispenser and are supported by eye-catching point of sale materials including posters and balloons." The new campaign packs will be rolled out to all stockists from early June, supported by a dramatic new Love your horse advertisement in national equestrian trade and consumer titles.
The campaign will build up momentum over the summer months and into autumn’s double dosing time with a series of authoritative, no-nonsense features and news stories from Strongid™-P’s veterinary advisor Ben Gaskell.
For further information please email: Strongid-P@pfizer.com
New Horse Passport Guidelines come into force from 1 July 2009 which will require horses to be microchipped. However a recent poll on Horse & Hound Online has revealed that 75 per cent of those questioned were unaware of the new microchip legislation.
With this in mind, Bayer has produced a comprehensive marketing support package for equine vets which provides an overview of the new Horse Passport Guidelines 2009 together with a clear and concise summary of its requirements for vets and horse owners.
The Tracer Advance equine package contains a handy laminated bullet point guide to the new regulations, practice posters, client leaflets, client leave pieces, pre-written articles for use in practice newsletters and local press, and PowerPoint presentations for client evenings.
Practices can apply for any of these items by contacting their Bayer Territory Manager.
Ceva Animal Health has produced a leaflet to help horse owners understand the cause, diagnosis and management of equine back pain.
The company says the management of back pain in the horse can be a particular challenge to vets and a source of frustration for owners. Early diagnosis is likely to be associated with a more favourable outcome but it's important to ensure that other causes of pain and poor performance such as lameness, are not contributing to the horse's clinical signs.
'Understanding back pain' explains the anatomy of the back, as well as the clinical signs of back pain, and how it is diagnosed, including the treatment options and the general prognosis. Copies of the new leaflet are available, free of charge, from your Ceva sales representative. Leaflets on 'Understanding bone spavin', 'Understanding navicular disease', 'Understanding sacroiliac disease' and 'Equidronate discharge instructions', are also available.
For further information contact your local Ceva representative or Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB, Telephone +44 (0) 1494 781510.
The Equine Veterinary Journal (EVJ) has published a free online collection of articles which explain the current understanding of equine antimicrobial resistance and how the profession can preserve the effectiveness of these essential medicines.
The new collection comprises ten clinical reports and studies and three editorials covering current trends on bacterial populations, risk factors and the appropriate use of antimicrobials in practice.
A clinical report on the changes in bacterial populations in foals with sepsis raises the question whether the emergence of resistance in horses has occurred as a result of antibiotic use in humans, with nosocomial spread from human handlers in foals. Studies on the prevalence of faecal carriage of antimicrobial resistant E. coli show their prevalence to be common in normal horses in the community in the UK, although MRSA carriage was rare. Data suggested transmission of resistant bacteria from animals receiving antibiotics may result in carriage of bacteria by in contact animals.
The need for judicious use of antimicrobials is reinforced in a study on antimicrobial-associated diarrhoea in three equine referral practices. Two papers investigate both prescribing practice in the UK and the impact of antimicrobial use on infection and pyrexia in hospitalised horses, concluding that there are opportunities for more targeted, ‘smart’, use antimicrobials in the perioperative period, rather than simply more antimicrobials.
The final study discusses a low-cost syndromic surveillance model for monitoring healthcare associated infection in clinical practice to provide a realistic benchmark against which other hospitals may compare antimicrobial study data.
Three supporting editorials complete the online collection, giving comment on the overall situation of antimicrobial resistance in the horses, including the current political situation and antimicrobials and surgical site infection.
Professor Peter Clegg, Associate Editor of the Equine Veterinary Journal said: "It remains to be determined how big a problem antimicrobial resistance will become for the equine veterinary profession, either through greater difficulties in treating horses, or through political pressure to restrict access to antimicrobials. Meanwhile the EVJ remains committed to the promotion of responsible stewardship to best preserve the efficacy of the drugs we have got for as long as we can."
Mark Bowen, President of the British Equine Veterinary Association and guest editor said: "BEVA has a long-term commitment to promoting responsible antimicrobial use throughout the profession and supporting EAAD through the PROTECT ME brand. This year we have released resources around Education, aimed at the profession through EVJ and to the horse owning public through development of material that can be provided alongside antimicrobial dispensing. The work of the equine profession in preserving the highest priority antimicrobials will ensure efficacy can be retained for as long as is possible."
The antimicrobial online collection is available free online at: http://onlinelibrary.wiley.com/journal/10.1001/(ISSN)2042-3306/homepage/antimicrobial_resistance.htm
A European study undertaken in horses to evaluate the efficacy of the key anthelmintic molecules fenbendazole, pyrantel, ivermectin and moxidectin in treating equine cyathostomins, has confirmed that resistance is developing against all the molecules with the exception of moxidectin.
Resistance to fenbendazole was highlighted as a particular issue with 80% of the yards tested in the UK and Germany showing resistance. Resistance to pyrantel also proved to be increasingly prevalent while cases of ivermectin resistance were emerging.
The Fort Dodge-sponsored study, the largest of its kind so far undertaken, took place during 2008 and was led by scientific teams from veterinary faculties in Italy and Germany. It was based on Faecal Egg Count Reduction Tests (FECRTs) of 1,704 horses at 102 yards in Italy, Germany and the UK. The calculation of FECR data was performed employing bootstrap analysis of group arithmetic means.
The study concluded that:
According to Dr Donato Traversa from the University of Teramo, Italy, who headed up the field work, the results confirm that single and even multiple drug resistance in equine cyathostomins is an increasing challenge in all three countries with resistance to fenbendazole and pyrantel a particular concern.
He said: "Our research highlights the necessity for vets, owners and managers to use those anthelmintic molecules that remain most effective in a manner which preserves their efficacy for as long as possible."
Professor Georg von Samson Himmelstjerna from Hannover University of Veterinary Medicine, which participated in the research, added: "Given the strong impact that resistant cyathostomins are likely to have on horse welfare, future parasite control plans should be based on integrated measures, involving both the correct use of anthelmintics, such as administering the correct dosing according to the animals weight, and only using products in the species for which it is licensed, as well as other approaches such as adequate pasture hygiene, low stocking rates and mixed grazing with other animals.
"We call on all concerned with equine health and welfare to take an active role in planning and monitoring effective worm control programs."
The authors say the research marks a significant step forward in understanding how veterinary surgeons and owners can more effectively manage and prevent outbreaks of the disease.
For the study, researchers from the RVC, the University of Cambridge, the Swedish University of Agricultural Sciences and Redwings Horse Sanctuary, analysed more than 500 S. equi samples from across the UK between 2016 and 2022.
In particular, they wanted to better understand the relative contribution of short-term (immediately post infection) versus long-term carriers (carriers that were infected months or years prior).
The samples were collected from clinical cases sent to diagnostic laboratories by veterinary surgeons seeking confirmation of infection.
Surplus samples were submitted to the Surveillance of Equine Strangles network and then cultured in the RVC’s research laboratory and their DNA extracted and sequenced to reveal each bacterium’s complete genetic code.
Adopting an approach that combined whole genome sequencing and epidemiological data, the researchers were able to trace how strains are related and have evolved.
With the use of computer programmes, they also tracked how genetically related strains spread between horses and across regions, over time.
By adopting this approach, the team was also able to pinpoint likely transmission events and chains of infection.
The main findings were:
The research highlights the need for early diagnosis, isolation and laboratory-confirmed clearance, particularly through guttural pouch testing, before assuming a horse is infection-free.
It also advocates for tighter biosecurity and movement protocols, especially when transporting horses across regions.
Dr Abigail McGlennon, former PhD student in the Department of Pathobiology and Population Sciences at the RVC, and lead author of the paper, said: “Strangles is a challenging and distressing disease for horses, owners, yards and vets, and this work has highlighted just how easily it can be spread across the UK in a short period of time.
“This study shows how important enhanced surveillance utilising epidemiological and genomic data is to investigate and understand strangles transmission across the UK.
"Our data highlights the importance of greater awareness and adoption of post-outbreak screening protocols to confirm freedom from infection, rather than owners assuming recovery based on the resolution of clinical signs.”
Reference
Dechra Veterinary Products, manufacturer and distributor of Equipalazone®, has launched a new information leaflet to support the Equine Passport scheme.
Since 2005, when equine passports became mandatory, 958,000 have been issued. The passport is a method of identification as well as a medical record and ensures that horses treated with veterinary medicines do not enter the human food chain.
“Many substances used in commonly prescribed equine medicines can only be given to horses not intended for human consumption,” says Giles Coley, Dechra’s managing director. “Under the passport scheme, owners must declare whether their horse is intended for human consumption.
The leaflet, which outlines the importance and benefits of the Equine Passport scheme, will be inserted into every box of Equipalazone Powder 100 sachets. It will also be made available for veterinary practices to hand out to their clients.
Practices wishing or order copies of the Equine Passport leaflet should contact Rachel Horton at Dechra on 01743 441 632.
Pfizer Animal Health is advising vets and horse owners to be on guard against the threat of West Nile Virus (WNV) in the UK, following a spate of outbreaks of the disease in several European countries this year.
West Nile Virus has recently made headline news because of a human outbreak in Greece which resulted in a number of deaths. Outbreaks have also occurred in Russia, Romania and Italy during 2010. West Nile Fever is a viral disease transmitted by mosquitoes, which carry the virus after biting infected birds. Primarily occurring between July and October, in line with typical peak activity of mosquitoes, it can have serious consequences on human and equine health, with severe cases resulting in fatal neurological disease.
There is no cure, though supportive treatment can aid recovery. However if the disease progresses to a state where the animal is not able to stand up, their chance of survival is considered low. Prevention of infection is difficult, but any steps that reduce mosquito numbers or the likelihood of horses and people being bitten may help to reduce the risk in areas where the disease is present. However, the only way to reduce the risk of an individual horse developing disease due to WNV is through vaccination.
Ben Gaskell, Pfizer's equine veterinary advisor said: "West Nile Virus may well become a very real threat to both horses and humans in Northern Europe. It is important for vets, horse owners and infectious disease experts to work together to mitigate its impact in the event of the virus becoming endemic across Europe. The rapid spread of the disease across North America is an illustration of what could potentially happen in Europe and it is important to remember there is no curative treatment - the only way to prevent clinical disease in horses is by vaccination."
Pfizer Animal Health supports the PrEquID (Prevention of Equine Infectious Disease) group, which consists of internationally recognised equine and infectious disease experts. The group was formed to develop guidelines on the prevention and control of a number of equine infectious diseases, on a global basis.
Klaus Osterrieder, Professor and Chair in the Institut für Virologie in the Veterinärfakultät at Freie Universität Berlin, Germany and a member of the PrEquID group advises: "Horse owners should ask their veterinarian for advice on appropriate prevention measures. Experience has shown that adopting a prudent prevention strategy can be a very effective way of managing this devastating disease."
Further information on WNV is available at www.westnile.eu.
ProteqFlu, the live attenuated canarypox equine influenza (EI) vaccine, has had its shelf life extended from 27 to 36 months.
Merial says the increased shelf life is the result of ongoing investment in vaccine research & development, and that the new data underpins the stability of modified live vaccine technology.
Merial highlights that ProteqFlu is the only equine flu vaccine in Europe to include the updated American clade 1 Ohio/03 strain in accordance with the OIE recommendations (2004).
Rather than offering 'death by Powerpoint', where large numbers of delegates are invited to sit and stare at a Powerpoint screen for an hour, followed by a few questions at the end, IVC and VetSurgeon.org invited a smaller, more intimate group to come and discuss a subject on Zoom, a recording of which was then made available for everyone else to watch later.
In the case of VetSurgeon.org, the first such meeting was 'Let's Talk About Small Animal Surgery' with Alasdair Hotston-Moore: https://www.youtube.com/watch?v=p1rD3zfcUZE
Meanwhile, IVC has based its recent CPD sessions about equine emergencies on a very similar model. During the event, short case studies were presented in a format which allowed for discussion all the way through.
IVC Evidensia Equine Clinical Board Vice Chair, Mark Tabachnik said: "We decided on a reflective, case-based approach rather than the usual monologue, where so much information is thrown at you, you’re lucky to catch a couple of snippets. I wanted something that was a little more relaxed and more collaborative, like a group of colleagues chatting about the cases from their night on call over a drink or two at the pub.”
It's a format which seems to be proving popular. Chessie Greenham of Fyrnwy Vets in Shropshire said: "Interesting cases that reflected on call life, worked through in an approachable style that is easily applied to real life scenarios."
Researchers at the Animal Health Trust are appealing for information from veterinary surgeons who have seen recent Eosinophilic Keratitis (EK) conditions, an emerging issue in UK equine ophthalmology.
The AHT says that despite the increased awareness of EK worldwide, the aetiopathogenesis of the disease remains poorly understood and probably underdiagnosed. The charity is looking to define the pathogenesis and determine why some horses are particularly susceptible to this condition, in particular looking for epidemiological links, environmental factors and parasitic infestation.
Many of the clinical signs of EK are non-specific and similar to other corneal conditions such as blepharospasm, chemosis, conjunctival hyperaemia, epiphora or perilesional oedema. More specific signs include caseous mucoid discharge and white/yellow plaques often localised in the peripheral cornea. The degree of pain varies and concurrent ulceration is almost always present. Conjunctivitis may also occur in association with the keratitis or as a unique disease entity.
EK can have variable clinical presentations, from a thick caseous accumulation to a more superficial plaque of “ground-glass” appearance. They may present as chronic non-healing ulcers that respond quickly to the use of topical steroids and/or ciclosporin, or present with marked ocular discomfort and require superficial keratectomy to resolve the condition.
Two different corneal locations are classically (though not exclusively) involved in EK, the medial perilimbal cornea, often under the third eyelid, or the lateral perilimbal cornea, which may progress axially towards the central cornea.
The charity is also providing free cytology tests for corneal scrapes to help vets diagnose EK earlier, thereby avoiding secondary complications that can lead to permanent visionary impairment.
If you have seen cases that have either been diagnosed as or that you suspect to be Eosinophilic Keratitis this year, contact Sonia Gonzalez-Medina on 01638 751000 Ext: 1203 or sonia.gonzalez-medina@aht.org.uk.
For more information and to download a copy of the submission form to accompany samples, visit www.aht.org.uk/EKstudy.
Intervet/Schering-Plough Animal Health, has launched a new guide entitled ‘Your guide to Exotic Diseases', to educate horse owners on these potentially fatal, insect-borne diseases, some of which are zoonotic.
Joining the company's guides on respiratory disease and vaccination, the leaflet features information on West Nile Virus, African Horse Sickness, Equine Infectious Anaemia (Swamp Fever) and Equine Encephalitis including overviews of each of the diseases and their clinical signs.
Spread by a variety of insect-borne vectors including midges, mosquitoes and horseflies, climate change is increasing the risk of exotic diseases having a severe impact on the country's equine industry. What's more, African Horse Sickness is transmitted from animal to animal by infected biting Culicoides midges, the same midges that carry the Bluetongue virus which has threatened UK livestock this year.
"It's essential that horse owners are aware of the threat of exotic diseases coming in from overseas and the clinical signs to look out for, especially during the summer and autumn months when diseases transmitted by insects are more likely to appear." comments Tim Zoch, Marketing Manager at Intervet/Schering-Plough Animal Health. "Our new leaflet features easy-to-understand overviews of each of the diseases to help educate owners, and practices can expect strong demand from their clients"
For further information about Intervet/Schering-Plough's range of horse owner guides, including ‘Your guide to Exotic Diseases', please contact your Intervet/Schering-Plough Account Manager or call the Veterinary Support Group on 01908 685685.
The pack contains:
For more information, contact your local Dechra equine sales manager.
Merial has launched a 'Vaccination Back on Track' promotion via vet practices that administer Merial vaccines.
Under the scheme, owners of all horses over 12 months of age that have not yet been vaccinated against equine influenza or are overdue a booster obtain a primary vaccination course at an attractive discounted rate. A tetanus component is also available if required.
Dr Emma Batson from Merial said: "With continuing cases of equine flu recorded in the UK, and a global increase in the number of serious outbreaks, it has never been more important to ensure that horses are protected against this underestimated threat.
"It's often not fully understood that equine flu can be transferred indirectly via inanimate objects such as horse boxes, fencing or human clothing. With just 37% of horses in the UK estimated to be vaccinated, this leaves a significant naive and vulnerable population at risk".
Merial says there is no limit on the number of horses that can be vaccinated, making it a particularly attractive offer for those with more than one horse or yard(s).
Participating practices have the option to run the scheme in any month between now and December 2009. For information, contact your Merial Territory Manager.
Currently fewer than one in ten veterinary students opt to go into equine practice. BEVA says it hopes that the new scheme will provide a broader base of students with an insight into the world of equine veterinary medicine and open more eyes to what’s great about being an equine vet.
Katie Roberts the President of the Association of Veterinary Students said: "This is a very exciting opportunity for students. Anecdotally, we know that some students can feel very daunted by equine practice, especially if they don’t come from a traditionally horsey background. Being able to become involved with BEVA at no cost means that they can get a true taste of the equine veterinary world in addition to their experiences on EMS, and I’m sure this will pique the interest of our members."
As part of their free membership, students will also have access to:
The initiative has been made possible with sponsorship from Baker McVeigh, CVS Group, IVC, Newmarket Equine Hospital, Rossdales, VetPartners, and XLVets.
For further information about student membership of BEVA visit: https://www.beva.org.uk/Join-BEVA/vet-student
The National Association of Veterinary Physiotherapists (NAVP) is calling for the Royal College of Veterinary Surgeons (RCVS) to establish an independent register of veterinary physiotherapy practitioners. According to the Association, such a register would eliminate individuals practicing without proper training and qualifications and raise the standard of veterinary physiotherapy by providing a disciplinary role.
NAVP President and leading veterinary anatomist Dr Sue Kempson is heading the NAVP campaign for the establishment of an independent register. In a letter to the President of the RCVS, Dr Kempson said: "Recognition by the veterinary profession of the role of physiotherapy in post-operative rehabilitation and in supporting both companion and performance animals is growing. However, we do believe that referring veterinary surgeons are increasingly faced with a dilemma caused by the wide differential between qualifications offered by the various organisations representing practitioners in areas such as physiotherapy. There is an urgent need for a distinction to be made between these different types of qualification. To this end, there should be a clearly defined independent register of practitioners with appropriately validated qualifications which are clearly understood by the veterinary profession."
In partnership with Harper Adams University College, the NAVP has introduced a fully-validated post-graduate course in veterinary physiotherapy which offers a choice of Post-Graduate Diploma or Masters Degree. Only one other professional body, the Association of Chartered Physiotherapists in Animal Therapy (ACPAT) currently offers a similar qualification at this level.
Dr Kempson said: "The establishment of a register of physiotherapists would greatly assist vets and their clients to make informed decisions on their choice of therapist. It would eliminate those individuals without proper training and qualifications and help raise the standard of veterinary physiotherapy by providing a disciplinary role. At present there are no sanctions on those people practicing without the necessary qualifications or those whose work is sub-standard or who are guilty of professional misconduct.
"We do not believe that such a register should rest with any individual professional body or be affiliated to specific educational courses. To have authority, it requires independence and a register held under the auspices of the Royal College of Veterinary Surgeons would carry the credibility that the veterinary profession requires."
The RSPCA has released the latest figures showing the extent of cruelty to animals in the UK.
In 2007, they show a:
"These animals are the helpless victims of our affluent, throwaway society," says Tim Wass, Chief Officer of the RSPCA Inspectorate. "They're bought on a whim and discarded when the novelty wears off. Today's must-have item quickly turns into tomorrow's cast-off.
"Worse still," added Tim, "some animals are violently abused because they don't meet their owners' unrealistic expectations: like the cat kicked to death for having muddy paws or the dog strangled with its lead for misbehaving."
But the year RSPCA reports that there has been good news too, with the success of the new Animal Welfare Act already starting to take effect. The new Act - which came into force during 2007 - has made it possible to take action sooner than ever before in situations where there are animal welfare concerns.
The Act is already producing powerful results in its first twelve months. Where animal welfare concerns have prompted the RSPCA to give advice to an animal owner, that advice was followed and the problems resolved 92% of the time, meaning that no further action was necessary. Tim said: "Even in these early days, the benefits of the new law are clear. Without the new Act, this year's cruelty figures could have been even more horrific."
He added: "Dogs have always borne the brunt of cruelty - from violent outbursts to extreme neglect. But that's what makes this year's horrendous 34% increase even more shocking: it's a massive increase on an already high figure."
It was hoped that last year's leap in convictions for cruelty to horses was an anomaly. But this year's figures show that the higher numbers have been maintained - they increased by 33% between 2005 and 2006 - and then increased by a further 13% to 119 in 2007.
The rise in banning orders is a big improvement on the previous year, which had actually recorded a fall. The new Animal Welfare Act obliges courts to explain their reasons if they don't impose a ban and this may have contributed to the increase. The new requirement seems to have focussed attention on preventative action which can prevent suffering and save lives.
Tim said: "The main reason we take people to court is to prevent cruelty being repeated. It's very reassuring to see the courts taking this seriously by issuing more and more banning orders, which prevent those convicted of cruelty from keeping animals in future."
The Federation of European Equine Veterinary Associations (FEEVA) and the European Federation of Farriers Associations (EFFA) have announced that they have joined forces to promote best practice in farriery.
The initiative is the result of recognition by both organisations that equine welfare is best served with the use of only properly trained farriers, working closely with veterinary surgeons as and when needed.
The organisations say that the main aims of the new partnership include:
The President of FEEVA, Professor Josh Slater said: "We look forward to working together at European level and encouraging member associations to do the same at national level, with the primary intention of enhancing equine health through first class farriery."
Pfizer is giving away a free equine weigh tape with every purchase of Equest & Equest Pramox (while stocks last), to help encourage accurate treatment against encysted small redworms this season.
According to the company, Equest & Equest Pramox are the only wormers in the UK that treat encysted small redworm in a single dose. Using a weigh tape to work out their horse's weight will help your clients avoid under dosing, which increases the risk of resistance development.
Pfizer says small redworms are the most common worms found in horses today. They can pose a very serious health risk to horses and it's important for owners to make sure that they are treated properly during the autumn or early winter.
Small redworms can grow up to 2.5cm in length and are thin and reddish in colour. Small redworm eggs are passed in the faeces and then hatch on pasture and continue to develop into more advanced larval stages before being ingested by the horse as it grazes. The larvae burrow deeply into the wall of the gut where they encyst and may account for up to 90% of the redworm burden in the horse1. Encysted small redworm will not show up in a Faecal Worm Egg Count - even if the horse has shown a negative or low count it could still be harbouring several million encysted small redworms2.
Encysted small redworms can remain dormant inside a horse for up to two years, but they usually 'wake-up' in late winter or early spring, developing and emerging from the gut wall all at the same time. In severe infestations mass emergence can lead to a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate3. Young horses of less than six years of age can often be at higher risk of the disease3 but small redworm can cause life-threatening illness at any time of year and in any age of horse.
Ben Gaskell, Pfizer's veterinary adviser said: "Treating encysted small redworms successfully in the late autumn or early winter is important to avoid the risk of larval cyathostominosis. It's important to advise your customers to choose a product that is licensed to treat the worms they are targeting and that they give the correct dose, by weighing their horse beforehand, as this will help preserve the efficacy of the drug used."
Pfizer's Does your wormer measure up campaign is backed with point of sale materials and a media campaign. To receive a free weigh tape, valued at £7 your clients need to buy a tube of Equest or Equest Pramox, fill in an application form and send Pfizer the batch and expiry flap from the pack. Pfizer will then send them a FREE Weigh Tape while stocks last.
For further information contact your Pfizer Account Manager.
References
1. Bairden K. et al (2001) Veterinary Record 148, 138-1412. Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑2423. McWilliam H. et al (2010) International Journal for Parasitology 40, 265-275
A new study, published in the Equine Veterinary Journal (EVJ)1 has concluded that whilst horse owners are increasingly looking to vets for worm control advice and use faecal worm egg counts more frequently, they remain largely unaware of the threat of resistance to dewormers and the importance of appropriate 'targeted' dosing.
The authors of the study say that although the findings are encouraging, they indicate that further effort is needed to help owners fully understand the issue of dewormer resistance, in order to help preserve the efficacy of dewormers currently available and protect the health and welfare of their horses.
According to the British Equine Veterinary Association (BEVA), resistance of equine gastrointestinal worms to the currently available dewormers is a serious problem. The association says small redworm are the greatest concern, given their very high prevalence, potential to cause life-threatening disease and high levels of resistance. Of the three classes of anthelmintic available for their control, there is now widespread resistance to benzimidazoles (e.g. fenbendazole) and tetrahydropyrimidines (e.g. pyrantel) and reduced effectiveness of macrocyclic lactones (ivermectin and moxidectin). With no new classes of dewormer on the horizon, it's essential that efficacy of existing effective products is preserved.
The study was conducted by a UK team, led by Claire Stratford, Horse Trust Clinical Scholar in Equine Medicine at the Royal (Dick) School of Veterinary Studies, and at Moredun Research Institute. The collaborators were also supported by funding from the Elise Pilkington Trust and Horserace Betting Levy Board.
The study examined equine helminth control practices in Scotland, and was based on responses from 193 questionnaires detailing the parasite control programmes of 993 horses and ponies. The results demonstrated a lack of awareness of the significance of dewormer resistance, with 86% of respondents stating that they were unaware of the presence of resistance on their yard. The majority were relatively unconcerned about dewormer resistance, assigning a score of only 6/10 (with 10 representing highest level of concern) when asked to grade how important they perceived it to be.
On a more positive note, many respondents stated that they involved their vet in planning control strategies. Faecal worm egg count (FWEC) analysis had been performed on 62% of yards and annual treatment frequency had been reduced accordingly. The macrocyclic lactones or related combination products were the most commonly administered products; however, owners did have misconceptions regarding the specific worms they should be targeting.
Although treatments licensed for use against encysted small redworm larvae were administered by 80% of respondents, only 57% perceived that they treated for this parasite stage. Similarly, only 78% of respondents believed they were treating for tapeworm when, in fact, 90% reported using a product licensed for tapeworm treatment.
While responses indicated increased implementation of strategic (44% respondents) or targeted control (40% respondents), variations in the apparent influence of the targeted approach on treatment practices suggested some confusion over this term. Claire Stratford said: "Targeted dosing involves using regular FWEC analysis to identify an individual's egg shedding level. This is currently considered best practice, when used in conjunction with annual dosing against encysted small redworm and tapeworm. The survey indicates a need for continued knowledge transfer, together with a consistent definition of 'targeted' treatment."
Professor Celia Marr, Editor of Equine Veterinary Journal said: "It's very encouraging to see that vet advice is being increasingly sought and it seems logical that the use of FWECs is rising accordingly. But, it is equally important that the information gained from the FWECs is used wisely. Resistance to dewormers is a major health concern that is with us right now and horse owners need to be made more aware of it."
Genitrix has announced that HY-50 Vet®, a sodium hyaluronate treatment for equine joints, has now been authorised for intravenous (IV) use.
Available until now for intra-articular (IA) use only, the company says HY-50 delivers the highest concentration of sodium hyaluronate on the market for the treatment of non-infectious joint inflammation and the enhancement of joint function.
Genitrix also says that, as IV application requires less specialist preparation than IA, HY-50 is now a practical solution for mixed practices with a smaller equine case load. Injected intravenously, the product will also benefit horses with multiple joint injuries.
HY-50 is presented in a 3 ml pre-loaded syringe, delivering 50 mg of sodium hyaluronate. It costs £55.50.
Rob Watkins, Marketing Director of Genitrix, said: "The efficacy of sodium hyaluronate is well established and we're delighted to be able to offer the IV route of administration. We know it will meet a real need in the market for a lameness treatment which is proven and simple to administer."
"Perhaps most importantly, in these financially difficult times, the high concentration of the product makes it a cost-effective approach compared with competitive products. We believe it will offer an affordable treatment option for owners who are anxious to treat their horses but may be discouraged by the high cost of many treatments."
For further information, see http://www.genitrix.co.uk/ or ring 01403 786345.
The Government's updated Exotic Animal Disease Contingency Plan was laid in Parliament today.
The revised plan is produced by Animal Health for Defra, and includes changes which have been subject to formal public consultation. This includes a framework response plan for dealing with exotic animal diseases and plans for responding to specific diseases including Foot and Mouth Disease, Avian Influenza and Newcastle Disease.
The changes to the plan reflect lessons identified from the incidents handled during 2008 and address recommendations made in Sir Iain Anderson's review of the 2007 outbreak of Foot and Mouth Disease and feedback from the public consultation.
Jane Kennedy, Minister for Farming and the Environment said: "An animal disease outbreak can be devastating for those concerned. Defra remains totally committed to ensuring we learn lessons from our experience of outbreaks, so that we can make sure we respond effectively in future".
The Contingency Plan is subject to ongoing revision based on the latest scientific advice, developments in policy, comments from stakeholders and operational partners together with the lessons identified from disease outbreaks. It can be accessed here:www.defra.gov.uk/animalh/diseases/control/contingency/index.htm